A 26-year-old woman comes to the psychiatric clinic for a follow-up evaluation regarding p… — USMLE Step 2 CK

A $26$ -year-old woman comes to the psychiatric clinic for a follow-up evaluation regarding persistent low mood, hypersomnia, and severe fatigue. She has an established diagnosis of bipolar II disorder. Six weeks ago, she began taking lamotrigine for a major depressive episode. Her dosage was gradually increased according to standard protocols to a maintenance dose of $200 \text{ mg}$ daily, which she has been taking consistently for the past $2$ weeks. Despite medication adherence, the patient states she feels "just as depressed as before" and struggles to complete basic daily tasks. Her medical history is notable for polycystic ovary syndrome, which is well-controlled with a combined ethinyl estradiol and norgestimate oral contraceptive pill. Vital signs are within normal limits. Laboratory testing reveals a serum lamotrigine concentration of $1.2 \mu\text{g/mL}$ (therapeutic reference range: $3-15 \mu\text{g/mL}$ ).

Which of the following is the most appropriate next step in management?

A
Discontinue the oral contraceptive pill
B
Discontinue lamotrigine and initiate citalopram monotherapy
C
Add valproate to the current medication regimen
Increase the dosage of lamotrigineAnswer
E
Discontinue lamotrigine and initiate carbamazepine

Answer

Increase the dosage of lamotrigine

The correct intervention is to increase the dosage of lamotrigine. Lamotrigine is primarily metabolized in the liver via glucuronidation by the enzyme UDP-glucuronosyltransferase 1A4 (UGT1A4). Estrogen, a key component of combined oral contraceptive pills, is a potent inducer of UGT1A4. This enzymatic induction significantly accelerates the clearance of lamotrigine, often reducing serum concentrations by

50\%

or more. Because this patient is symptomatic and has a confirmed subtherapeutic lamotrigine level resulting from this known pharmacokinetic interaction, the appropriate clinical step is to increase the lamotrigine dosage to achieve therapeutic efficacy. Often, female patients taking concurrent estrogen-containing contraceptives require up to double the standard maintenance dose of lamotrigine.

Step-by-Step Solution

Identify the primary clinical problem.

The patient has bipolar II depression and is symptomatic despite taking a standard maintenance dose of lamotrigine, with objective laboratory evidence of a subtherapeutic drug concentration.

Establishing the baseline clinical status is necessary to determine if the current regimen is adequate.

Analyze the patient's medication list for potential pharmacokinetic interactions.

The patient is taking a combined oral contraceptive pill containing ethinyl estradiol.

Drug-drug interactions are a primary cause of subtherapeutic medication levels in psychiatry, particularly with mood stabilizers.

Determine the mechanism of the drug-drug interaction.

Estrogen is a potent inducer of UDP-glucuronosyltransferase 1A4 (UGT1A4), the primary hepatic enzyme responsible for the glucuronidation and clearance of lamotrigine.

Understanding this metabolic pathway explains why the lamotrigine level is significantly lower than expected for a compliant patient on a

200 \text{ mg}

dose.

Select the safest and most effective clinical intervention.

The lamotrigine dosage must be increased to overcome the accelerated clearance and achieve a therapeutic serum level.

Adjusting the dose addresses the underlying pharmacokinetic issue without abandoning an effective first-line treatment or precipitating dangerous withdrawal toxicities.

Key Concept

Estrogen-containing oral contraceptives induce the glucuronidation (via UGT1A4) of lamotrigine, significantly decreasing its serum concentration and requiring a higher maintenance dose.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic